Non-Small Cell Lung Carcinoma – Drugs In Development, 2023
Powered by
Unlock hidden opportunities in the Pharmaceuticals industry
Global Markets Direct’s, ‘Non-Small Cell Lung Carcinoma – Drugs In Development, 2023’, provides an overview of the Non-Small Cell Lung Carcinoma pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Non-Small Cell Lung Carcinoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Non-Small Cell Lung Carcinoma and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note:
*Certain sections in the report may be removed or altered based on the availability and relevance of data.
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase
* Global Markets Direct, is a research brand owned and operated by GlobalData.
Scope
- The report provides a snapshot of the global therapeutic landscape of Non-Small Cell Lung Carcinoma
- The report reviews pipeline therapeutics for Non-Small Cell Lung Carcinoma by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Non-Small Cell Lung Carcinoma therapeutics and enlists all their major and minor projects
- The report assesses Non-Small Cell Lung Carcinoma therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Non-Small Cell Lung Carcinoma
Reasons to Buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Non-Small Cell Lung Carcinoma
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Non-Small Cell Lung Carcinoma pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Key Players
AbbVie IncAccendatech Co Ltd
Adagene Suzhou Ltd
Adaptimmune Therapeutics Plc
Agency for Science
Technology and Research
Akeso Inc
amcure GmbH
Amgen Inc
Andarix Pharmaceuticals Inc
Antengene Corp Ltd
Asher Biotherapeutics Inc
Astellas Pharma Inc
AstraZeneca Plc
BeiGene Ltd
Biomica Ltd
Boehringer Ingelheim International GmbH
BridgeBio Pharma Inc
Bristol-Myers Squibb Co
CARsgen Therapeutics Ltd
CDR-Life Inc
Coherus BioSciences Inc
Convalife
CSPC Pharmaceutical Group Ltd
Eli Lilly and Co
FUDAN University
Galera Therapeutics Inc
GenFleet Therapeutics (Shanghai) Inc
GSK plc
Harbour BioMed (Guangzhou) Co Ltd
HK inno.N Corp
Humanetics Corp
Hummingbird Bioscience Pte Ltd
Icahn School of Medicine at Mount Sinai
Immatics NV
ImmuneOnco Biopharmaceuticals (Shanghai) Co Ltd
Immutep Ltd
InnoPharmaScreen Inc
Instil Bio Inc
Invectys SA
Ipsen SA
J2H Biotech
Jiangsu Hengrui Medicine Co Ltd
Johnson & Johnson
Komipharm International Co Ltd
Laekna Therapeutics Shanghai Co Ltd
Les Laboratoires Servier SAS
Likang Life Sciences Holdings Ltd
Mabpro as
Metagone Biotech Inc
Minneamrita Therapeutics LLC
Moderna Inc
MOYA Bio
National Cancer Institute US
Nippon Kayaku Co Ltd
Ocean Biomedical Inc.
pacDNA LLC
Pfizer Inc
Ribon Therapeutics Inc
Sagimet Biosciences Inc
Shanghai Junshi Biosciences Co Ltd
Shenzhen Chipscreen Biosciences Co Ltd
Sichuan Huiyang Life Science and Technology Corp
SK Biopharmaceuticals Co Ltd
Suzhou Maximum Bio-tech Co Ltd
Systimmune Inc
Taiwan Liposome Co Ltd
The First Affiliated Hospital of the University of Science and Technology of China
Torqur AG
Turgut Ilaclari AS
U.S. National Institutes of Health
Valo Health LLC
WellMarker Bio Co Ltd
Wuhan YZY Biopharma Co Ltd
Xencor Inc
Xiangxue Life Sciences
Y-Biologics Inc
Zhuhai Beihai Biotech Co Ltd